- Summit Therapeutics Inc. (NASDAQ:SMMT) is set to release its quarterly earnings on October 20, 2025, with Wall Street expecting an earnings per share of -$0.14 and projected revenue of approximately $77.2 million.
- The company will also provide an ESMO Data Update and Third Quarter Earnings Call, focusing on the HARMONi-6 clinical trial results.
- Despite its innovative efforts in antibiotics and oncology, SMMT faces financial challenges with a negative P/E ratio of -21.87 and a negative enterprise value to operating cash flow ratio of -77.47.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company focused on developing innovative therapies. The company is known for its work in the field of antibiotics and oncology. Summit collaborates with partners like Akeso, Inc. to advance its clinical trials. The company faces competition from other biotech firms in the race to develop new treatments.
On October 20, 2025, SMMT is set to release its quarterly earnings. Wall Street expects the earnings per share to be -$0.14, with projected revenue of approximately $77.2 million. This release coincides with an ESMO Data Update and Third Quarter Earnings Call, where data from the HARMONi-6 clinical trial will be disclosed.
The HARMONi-6 trial, conducted in China and sponsored by Akeso, Inc., features a novel bispecific antibody. This trial is part of Summit’s efforts to bring first-in-class treatments to market. Despite these advancements, SMMT has a negative price-to-earnings (P/E) ratio of -21.87, indicating current unprofitability.
Financially, SMMT faces challenges with a negative enterprise value to operating cash flow ratio of -77.47, suggesting difficulties in generating cash flow from operations. The earnings yield is also negative at -4.57%, further highlighting the company’s lack of profitability. However, SMMT maintains a low debt-to-equity ratio of 0.02, showing minimal reliance on debt.
Additionally, SMMT’s current ratio stands at 5.13, indicating a strong ability to cover short-term liabilities with short-term assets. This financial stability provides a cushion as the company navigates its clinical trials and aims for future profitability.
